Developing more precise diagnostic approaches to predict cancer progression and prognosis is the key to precision medicine. The mission of the Translational Oncology Research Unit mirrors at specific genomic and epigenetic alterations in both solid and hematopoietic malignancies that hold the potential to represent novel cancer biomarkers or druggable targets. This is pursued through genome wide approaches applied to cell systems, animal models, tissues and biological fluids (ctDNA and non-coding RNAs) of cancer patients.